HRA Pharma - David Wright's appointment
In order to accelerate HRA Pharma’s growth as an innovative OTC company, the company’s Supervisory Board has appointed David Wright as Chief Executive Officer, effective April 3rd, in place of François Vuillet.
HRA Pharma’s strategic agenda initiated in 2016 sets the ambition to become a global innovative OTC player, bringing solutions and access to patients globally. Supported by its majority shareholders, Astorg and Goldman Sachs Merchant Banking Division, this strategy will allow HRA to consolidate its role as a driver of innovation in women’s healthcare, endocrinology and consumer healthcare, while accelerating its international expansion.
International development, particularly in the US, is of the utmost importance to HRA Pharma today. HRA Pharma is thus currently working on several projects that are aimed at bringing about a real revolution in American women’s access to contraception. Through these projects, HRA hence intends to position itself as a leading company bringing access to effective contraception to women worldwide.
The appointment of David Wright, a renowned leader in the OTC space, as CEO of HRA Pharma illustrates the company’s willingness to accelerate the deployment of this strategy. David Wright, a British national, has over 25 years of experience in the pharmaceutical industry. Most recently, David Wright was Senior Vice-President Global OTC Operations of Boehringer-Ingelheim and headed Boehringer Ingelheim’s OTC franchise. David led the rapid organic development of this franchise as one of the fastest growing OTC platforms globally with presence in all key markets and strong global brands.
“I am very proud and excited to join a high growth and innovative group. I am motivated to lead HRA employees, which have proven their great capacities in delivering innovative care to women and patients globally. My ambition is to build on these solid foundations, lead the teams and continue to expand HRA’s footprint”, comments David Wright, who this week takes on his new responsibilities at the head of HRA Pharma.
The Supervisory Board wishes to express its gratitude to François Vuillet for the work that he has accomplished during his fifteen-year career at HRA Pharma and for his vital contributions to the company’s rapid development.
HRA Pharma
HRA Pharma is a privately-held European pharmaceutical company that designs products and targets therapeutic gaps in the areas of women’s health, consumer health and endocrinology, and uses innovative marketing solutions and socially conscious programs to promote healthy management of drugs and diseases. Headquartered in Paris, France and with subsidiaries across Western Europe, HRA Pharma has built a strong network of R&D, manufacturing, distribution and NGO partners that enables it to satisfy critical patient needs and improve patient health across the globe. Visit www.hra-pharma.com for more information.
David Wright’s biography
Former Senior Vice President Global OTC operations of Boehringer-Ingelheim Consumer Healthcare, David Wright has 25 years of professional experience in the field of consumer healthcare. He started his career at Boots Consumer Healthcare prior to joining Sandoz (formerly Novartis) in 1992 as Sales Director. In 1997, David Wright took over as UK Director of Boehringer-Ingelheim Consumer Healthcare, before becoming Global Marketing Director in 2004, and Senior Vice President Global OTC operations in 2010. In this capacity, he had a global responsibility over Boehringer Ingelheim’s activities in the OTC space, with sales in 63 countries (1.8 billion EUR in turnover).
Further Information
Delivering consistent performance
across every investment
Related Hub content
Astorg completes acquisition of Microbiology business from Thermo Fisher Scientific, establishing an independent global diagnostics specialist
Astorg-backed CordenPharma acquires AmbioPharm, strengthening its position as a leading global peptide development and manufacturing platform
Astorg unveils, Nexpring Health, the new brand identity of its global medtech company in assisted reproductive technology
Astorg continues to bolster its newly combined global leader in assisted reproductive technology by acquiring FUJIFILM Irvine Scientific’s medical media business
Astorg completes take Private of Hamilton Thorne and concurrent acquisition of Cook Medical Reproductive Health, establishing a global leader in assisted reproductive technology consumables and equipment
CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe
Astorg completes acquisition of Microbiology business from Thermo Fisher Scientific, establishing an independent global diagnostics specialist
Astorg-backed CordenPharma acquires AmbioPharm, strengthening its position as a leading global peptide development and manufacturing platform
Astorg unveils, Nexpring Health, the new brand identity of its global medtech company in assisted reproductive technology